- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT01220726
Botox for the Treatment of Overactive Bladder Secondary to Benign Prostatic Obstruction
Randomized Double-blind Placebo Controlled Trial of Intradetrusor Injections of Botox for the Treatment of Refractory Overactive Bladder Secondary to Benign Prostatic Obstruction-BTX0621
Panoramica dello studio
Descrizione dettagliata
Group 1 n=20 BOTOX® 200U Group 2 n=20 Placebo BOTOX® (saline) At Visit 2 (Treatment, Day 0), subjects will receive one injection cycle of BOTOX (200U) or placebo (saline). The study duration is approximately 284 days and consists of a Screening Visit (Day -7 to -14), a Treatment/Randomization Visit (Visit 2, Day 0), and Follow-up Visits at 7, 30, 90, 180, and 270 Days. Telephone Follow-ups will be made 3 days following the injection cycle.
Subjects demonstrating an insufficient response to treatment may receive an open-label injection cycle of BOTOX (200U) at Day 90. Subjects receiving this injection will re-commence Follow-up Visits and be followed for an additional 270 days.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 3
Contatti e Sedi
Luoghi di studio
-
-
New York
-
New York, New York, Stati Uniti, 10065
- Weill Cornell Medical Center
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Male outpatients of any race, between 40 and 90 years of age.
- Clinical signs and symptoms of frequency (>=8 micturitions/day) and urgency (>=2 episodes/day).
- Urodynamic history consistent with OAB that developed in conjunction with BPO and that persists for at least 3 months post TURP or PVP, RRP or other obstruction relieving procedure.
- OAB inadequately controlled with anticholinergic medications, as per Investigator opinion.
- Qmax >12mL/s with a voided volume of >125mL.
- IPSS >12, with IPSS QoL >3 at study Visit 1.
- Willing to use clean intermittent catheterization (CIC) to empty the bladder or is willing to have an indwelling catheter, if necessary following study treatment.
- Able to understand the requirements of the study, including completing questionnaires and signing Informed Consent/HIPAA.
Exclusion Criteria:
- Known history of interstitial cystitis, uninvestigated hematuria, bladder outlet obstruction due to vesical neck contracture, mullerian duct cysts, urethral obstruction due to stricture/valves/sclerosis of urethral tumor, radiation cystitis, genitourinary tuberculosis, bladder calculi, or detrusor-sphincter dyssynergia.
- Known history of clinically significant cardiovascular disease, cerebrovascular disease, or arrhythmia.
- History of spinal cord injury or multiple sclerosis, or other neurological disease which may be contributing to OAB.
- Known history of hydronephrosis.
- Current indwelling catheter, or removal of chronic catheter <1 month prior to study entry.
- Non-compliance with wash-out periods for prohibited medications/therapies (Supplement I).
- Evidence of Urinary Tract Infection according to local standard of care.
- Serum PSA of >10ng/mL.
- 24 hour total volume voided >3000 mL of urine. [As determined by completion of a patient bladder diary during the screening period]
- Medical condition that may increase their risk of exposure to botulinum toxin including diagnosed Myasthenia Gravis, Eaton-Lambert Syndrome, Amyotrophic Lateral Sclerosis or any other disease that might interfere with neuromuscular function.
- Allergy or sensitivity to any component of BOTOX® (Section 5.2).
- Known uncontrolled systemic disease.
- Evidence of recent alcohol/drug abuse.
- Subjects who, in the opinion of the Investigator, have a significant condition that puts them at significant risk, may confound study results, or interfere with study participation.
- History of poor cooperation, non-compliance with medical treatment, or unreliability.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Quadruplicare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Comparatore attivo: Botox
200U onabotulinumtoxinA (botox)
|
Botox injection
|
Comparatore placebo: Placebo
200U Saline
|
Iniezione di placebo
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Urinary Frequency
Lasso di tempo: From Baseline to Day 270
|
This is the measure of urinary frequency at baseline for those in the placebo and botox arms to day 270
|
From Baseline to Day 270
|
Urgency
Lasso di tempo: From Baseline to Day 270
|
This measured the degree of urinary urgency using a 3-day voiding diary.
Patients were assessed for the number of urgency episodes they had by answering yes or no.
|
From Baseline to Day 270
|
Quality of Life (QoL)
Lasso di tempo: From Baseline to Day 270
|
Quality of Life (QoL) is from the ICIQ-QAB (international Consultation of Incontinence Overactive Bladder) Questionnaire.
It is scored 25-160 and those with higher scores have higher impact on quality of life.
|
From Baseline to Day 270
|
International Consultation on Incontinence Questionnaire (ICIQ)
Lasso di tempo: From Baseline to Day 270
|
ICIQ is a brief validated instrument that is comprehensive for the assessment of incontinence and measures frequency, severity and impact on quality of life.
There are a total of 23 items.
The overall score ranges from 1-84 with greater values indicating increased symptom severity.
Bother scales are not incorporated in the overall score but indicate impact of individual symptoms for the patient.
|
From Baseline to Day 270
|
Postvoid Residual Volume (PVR)
Lasso di tempo: From Baseline to Day 270
|
Postvoid residual volume (PVR) is the volume of fluid remaining in the bladder immediately after the completion of micturition.
|
From Baseline to Day 270
|
Maximum Flow Rate (Qmax)
Lasso di tempo: From Baseline to Day 270
|
Qmax is the the maximum recorded flow rate
|
From Baseline to Day 270
|
International Prostate Symptom Score (IPSS)
Lasso di tempo: From Baseline to Day 270
|
International Prostate Symptom Score (IPSS) -is a 7 point scale used to screen, track and manage symptoms associated with BPH.
The symptoms questions include feeling of incomplete bladder emptying, frequency, intermittency, urgency, weak stream, straining and nocturia.
Scores range from 1 to 5 for a total of maximum 35 points (0-7 Mildly symptomatic, 8-19 Moderately symptomatic, 20-35 Severely symptomatic)
|
From Baseline to Day 270
|
Collaboratori e investigatori
Investigatori
- Investigatore principale: Alexis Te, Weill Medical College of Cornell University
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- BTX0621
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Botox
-
li nguyenSconosciutoSpasticità degli arti superiori unilateralmente negli adulti con storia di ictus | Aumento del tono muscolare nei flessori del gomito, del polso, delle dita e del pollice.Stati Uniti
-
ASIS CorporationSconosciutoEmicrania cronica più di 15 giorni al mese e che dura 4 ore al giorno o più.Stati Uniti
-
li nguyenSconosciutoDistonia cervicale Adulti, | Posizione anormale della testa e dolore al collo per questi 7 gruppi muscolari: splenio, scaleno, sterno-cleido-mastoideo, elevatore della scapola, semispinale, trapezio e longissimus.Stati Uniti
-
Oslo University HospitalReclutamentoFascite plantare | Rigidità del gastrocnemioNorvegia
-
GlaxoSmithKlineReclutamento
-
Oregon Health and Science UniversityAllerganCompletatoSolchi glabellari
-
GlaxoSmithKlineCompletatoSpasticità, post-ictus
-
US Department of Veterans AffairsRitiratoVescica iperattiva | Incontinenza urinariaStati Uniti
-
University of British ColumbiaRitirato
-
University of British ColumbiaCompletatoPiede torto idiopatico (Talipes Equinovarus)Canada